Compounds > mvt 101
Page last updated: 2024-12-08

mvt 101

Description

MVT 101: peptide inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID449521
CHEMBL ID48996
MeSH IDM0171624
PubMed CID78171629
MeSH IDM0171624

Synonyms (24)

Synonym
(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s,3r)-2-acetamido-3-hydroxy-butanoyl]amino]-3-methyl-pentanoyl]amino]hexyl]amino]hexanoyl]amino]-n-[(1s)-1-carbamoyl-4-guanidino-butyl]pentanediamide
acthrilenle[nch2]nleglnargnh2
l-argininamide, n-acetyl-l-threonyl-l-isoleucyl-l-norleucyl-y(ch2-nh)-l-norleucyl-l-glutaminyl
mvt-101
2AOG
ace-t-i-nle-r-nle-q-r
n-1465 ,
2AVQ
peptide inhibitor p2/nc
2AVM
bdbm13936
(2s)-n-[(1s)-4-carbamimidamido-1-carbamoylbutyl]-2-[(2s)-2-{[(2s)-2-[(2s,3s)-2-[(2s,3r)-2-acetamido-3-hydroxybutanamido]-3-methylpentanamido]hexyl]amino}hexanamido]pentanediamide
chembl48996 ,
n-{(2s)-2-[(n-acetyl-l-threonyl-l-isoleucyl)amino]hexyl}-l-norleucyl-l-glutaminyl-n~5~-[amino(iminio)methyl]-l-ornithinamide
2nc ,
(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3s)-2-[[(2s,3r)-2-acetamido-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]hexyl]amino]hexanoyl]amino]-n-[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
mfcd00133570
ac-thr-ile-nle-psi(ch2nh)nle-gln-arg-nh2
128657-47-6
CS-0107649
HY-P2054
AKOS040746138
125552-93-4
mvt 101
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (20)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Hiv-1 ProteaseHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.53000.53000.53000.5300AID977610
Chain B, Hiv-1 ProteaseHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.53000.53000.53000.5300AID977610
Chain A, Hiv-1 ProteaseHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.53000.53000.53000.5300AID977610
Chain B, Hiv-1 ProteaseHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.53000.53000.53000.5300AID977610
Chain A, Pol PolyproteinHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.53000.53000.53000.5300AID977610
Chain B, Pol PolyproteinHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.53000.53000.53000.5300AID977610
Chain A, Hiv-1 Protease (retropepsin)Human immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.53000.53000.53000.5300AID977610
Chain B, Hiv-1 Protease (retropepsin)Human immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.53000.53000.53000.5300AID977610
Chain A, HIV-1 proteaseHuman immunodeficiency virus 1Ki21.50000.00058.605841.0000AID977610
Chain B, HIV-1 proteaseHuman immunodeficiency virus 1Ki21.50000.00058.605841.0000AID977610
Chain A, Pol polyproteinHuman immunodeficiency virus 1Ki21.50000.00058.605841.0000AID977610
Chain B, Pol polyproteinHuman immunodeficiency virus 1Ki21.50000.00058.605841.0000AID977610
Chain A, Pol polyproteinHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki21.50000.00058.605841.0000AID977610
Chain B, Pol polyproteinHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki21.50000.00058.605841.0000AID977610
Chain A, Pol polyproteinHuman immunodeficiency virus 1Ki21.50000.00058.605841.0000AID977610
Chain B, Pol polyproteinHuman immunodeficiency virus 1Ki21.50000.00058.605841.0000AID977610
Chain A, Pol polyproteinHuman immunodeficiency virus 1Ki21.50000.00058.605841.0000AID977610
Chain B, Pol polyproteinHuman immunodeficiency virus 1Ki21.50000.00058.605841.0000AID977610
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (BRU ISOLATE)Ki12.11750.00000.08283.3000AID1797112
Protease Human immunodeficiency virus 1IC50 (µMol)1.90000.00010.22487.3200AID162056
Protease Human immunodeficiency virus 1Ki0.77810.00000.04433.1000AID160777; AID162713
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1797112Protease Inhibition Assay from Article 10.1016/j.jmb.2005.09.095: \\Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.\\2005Journal of molecular biology, Dec-09, Volume: 354, Issue:4
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005Journal of molecular biology, Dec-09, Volume: 354, Issue:4
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
AID1811Experimentally measured binding affinity data derived from PDB2005Journal of molecular biology, Dec-09, Volume: 354, Issue:4
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
AID162713Binding affinity against HIV-1 aspartic proteinase was determined1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase.
AID160777Binding affinity to HIV-1 protease1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Three-dimensional pharmacophores from binding data.
AID162056Inhibition of HIV-1 Protease.1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005The FEBS journal, Oct, Volume: 272, Issue:20
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
AID1811Experimentally measured binding affinity data derived from PDB2005The FEBS journal, Oct, Volume: 272, Issue:20
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.56)18.7374
1990's12 (66.67)18.2507
2000's4 (22.22)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		1.9810aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
n-acetylseryl-leucyl-asparaginyl(phenylalanyl-hydroxyethylamino-prolyl)isoleucyl-valyl methyl ester
N-acetylseryl-leucyl-asparaginyl(phenylalanyl-hydroxyethylamino-prolyl)isoleucyl-valyl methyl ester: inhibitor of HIV Protease; structure given in first source; RN given is for (S-(R*,R*)) isomer		1.9810
sc 52151
SC 52151: HIV protease inhibitor containing the (hydroxylethyl)urea isostere; R-isomer is 1700 times more active than S-isomer		1.9810asparagine derivative
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		1.9810L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
skf 107457
SKF 107457: structure given in first source		1.9810
85548e
85548e: structure given in first source; RN given for (2S-(2R*,4R*,5R*))-isomer		1.9810
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		2.0210dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
pepstatin
pepstatin: inhibits the aspartic protease endothiapepsin		1.9810pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
streptomyces pepsin inhibitor
[no description available]		2.3920
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		210isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		1.9910L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
kynostatin 272
kynostatin 272: structure given in first source; contains allophenylnorstatine as a transition-state mimic		210peptide
abbott 77003
Abbott 77003: a symmetry-based inhibitor of HIV-1 protease		1.9910
a 74704
A 74704: structure given in first source		1.9910
a 76889
A 76889: backbone structure gvien in first source		1.9910
jg 365
[no description available]		2.9140
85548e
85548e: structure given in first source; RN given for (2S-(2R*,4R*,5R*))-isomer		1.9710
u 75875
U 75875: structure given in first source		1.9710
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		1.9810benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Acquired Immune Deficiency Syndrome
[description not available]		01.9810
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		01.9810
chemdatabank.com